Artiva Biotherapeutics’ (ARTV) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report released on Friday, RTT News reports. Wedbush currently has a $18.00 price objective on the stock.

Several other research analysts have also recently commented on the stock. Cantor Fitzgerald started coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an overweight rating and a $23.00 target price for the company. TD Cowen assumed coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a buy rating for the company. Jefferies Financial Group assumed coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a buy rating and a $21.00 price target on the stock. Finally, Needham & Company LLC reissued a buy rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Friday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Artiva Biotherapeutics currently has an average rating of Buy and an average target price of $21.25.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $11.54 on Friday. Artiva Biotherapeutics has a twelve month low of $9.71 and a twelve month high of $16.00.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, Director Yong-Jun Huh purchased 2,083,332 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was acquired at an average price of $12.00 per share, with a total value of $24,999,984.00. Following the acquisition, the director now directly owns 3,306,900 shares of the company’s stock, valued at approximately $39,682,800. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Yong-Jun Huh purchased 2,083,332 shares of Artiva Biotherapeutics stock in a transaction that occurred on Monday, July 22nd. The shares were acquired at an average price of $12.00 per share, with a total value of $24,999,984.00. Following the completion of the transaction, the director now directly owns 3,306,900 shares of the company’s stock, valued at approximately $39,682,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Global Strategic Fund I. Venbio purchased 416,666 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The stock was bought at an average price of $12.00 per share, for a total transaction of $4,999,992.00. Following the transaction, the insider now directly owns 1,936,637 shares of the company’s stock, valued at approximately $23,239,644. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.